A Study On The Prediction of Neoadjuvant Efficacy For Rectal Cancer Based On MR Cytometry Imaging and Deep-radiomics

Condition(s) studied

Study summary

This study employed MR cytometry imaging combined with deep-radiomic research methods to predict the heterogeneity of rectal cancer, and constructed a model to predict the sensitivity to neoadjuvant therapy and potential mechanisms, assisting clinicians in early identification of high-risk tumors and patients with treatment-susceptible rectal cancer, and selecting individualized treatment plans, thereby improving patient prognosis. To this end, the investigators need to collect the clinical diagnosis and treatment data of patients, surgical and biopsy pathological information, pre-treatment rectal MRI images and colonoscopy biopsy tissue sections, and follow up on the surgical pathological results and recurrence of patients. This study is a non-interventional diagnostic study, which does not interfere with the routine diagnosis and treatment of patients, does not affect any medical rights of patients, and does not increase any medical risks.

Eligibility

Primary outcome measure(s)

• Pathological complete response — One month after surgery
• Pathological tumor regression grade — One month after surgery
• progression-free survival — From date of surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

Trial sites (1)

More Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials in China

Other trials for the same condition